BCL2 and myelofibrosis: Navitoclax is a novel anti-apoptotic B cell leukemia 2 (Bcl-2) inhibitor that, when combined with ruxolitinib in phase II trials, has shown significant promise in the treatment of intermediate-2 to high-risk myelofibrosis [1].